Daniele Rossini

5PUBLICATIONS
30CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jun 04, 2026
Reply to: "Understanding the Contribution of Anti-EGFR Reinduction to Overall Survival in the TRIPLETE Study" and "TRIPLETE But Incomplete? Accounting for Postprogression Therapy When Interpreting Overall Survival".

|Jan 08, 2026
Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study.

Veronica Conca, Daniele Rossini, Carlotta Antoniotti

|Nov 26, 2025
Prediction of Microsatellite Instability in Colorectal Cancer Using Two Internally Validated Radiomic Models.

Antonio Galluzzo, Ginevra Danti, Linda Calistri

|Apr 18, 2025
Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal Cancer.

Roberto Moretto, Marco Maria Germani, Martina Carullo

|Jul 17, 2024
Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer.

Marinde J G Bond, Maarten van Smeden, Koen Degeling

Pageof 1

Frequent Collaborators

4 joint publications

Chiara Cremolini

3 joint publications

Carlotta Antoniotti

3 joint publications

Sara Lonardi

3 joint publications

Veronica Conca